Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605

• Main Authors: Buchanan Fritz G, Donawho Cherrie, Sheppard George S, Johnson Eric F, Soni Niru B, Grudzien Meagan M, Zhang Qian, Hubbard Robert D, Wang Yi-Chun, Meulbroek Jonathan A, Jung Paul M, Pappano William N, Davidsen Steven K, Bell Randy L, Wang Jieyi
• Format: Article
• Language: English
• Published: BMC 2009-09-01
• Series: BMC Cancer
• Online Access: http://www.biomedcentral.com/1471-2407/9/314

<p>Abstract</p> <p>Background</p> <p>The insulin-like growth factor (IGF) axis is an important signaling pathway in the growth and survival of many cell and tissue types. This pathway has also been implicated in many aspects of cancer progression from tumorigenesis to metastasis. The multiple roles of IGF signaling in cancer suggest that inhibition of the pathway might yield clinically effective therapeutics.</p> <p>Methods</p> <p>We describe A-928605, a novel pyrazolo [3,4-<it>d</it>]pyrimidine small molecule inhibitor of the receptor tyrosine kinases (IGF1R and IR) responsible for IGF signal transduction. This compound was first tested for its activity and selectivity via conventional <it>in vitro </it>kinome profiling and cellular IGF1R autophosphorylation. Additionally, cellular selectivity and efficacy of A-928605 were analyzed in an IGF1R oncogene-addicted cell line by proliferation, signaling and microarray studies. Finally, <it>in vivo </it>efficacy of A-928605 was assessed in the oncogene-addicted cell line and in a neuroblastoma model as a single agent as well as in combination with clinically approved therapeutics targeting EGFR in models of pancreatic and non-small cell lung cancers.</p> <p>Results</p> <p>A-928605 is a selective IGF1R inhibitor that is able to abrogate activation of the pathway both <it>in vitro </it>and <it>in vivo</it>. This novel compound dosed as a single agent is able to produce significant growth inhibition of neuroblastoma xenografts <it>in vivo</it>. A-928605 is also able to provide additive effects when used in combination with clinically approved agents directed against EGFR in non-small cell lung and human pancreatic tumor models.</p> <p>Conclusion</p> <p>These results suggest that a selective IGF1R inhibitor such as A-928605 may provide a useful clinical therapeutic for IGF pathway affected tumors and warrants further investigation.</p>